2018 News Releases

Webcast ImageWebcast - Live
AtriCure, Inc. at Piper Jaffray 30th Annual Healthcare Conference
11/28/18 at 8:00 a.m. ET
AtriCure, Inc. at Piper Jaffray 30th Annual Healthcare Conference
Wednesday, November 28, 2018 8:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast - Replay
AtriCure, Inc. at Stifel 2018 Healthcare Conference
11/14/18 at 1:15 p.m. ET
AtriCure, Inc. at Stifel 2018 Healthcare Conference
Wednesday, November 14, 2018 1:15 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast - Replay
AtriCure, Inc. Earnings Conference Call
11/01/18 at 4:30 p.m. ET
AtriCure, Inc. Earnings Conference Call
Thursday, November 1, 2018 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast - Replay
AtriCure, Inc. at Morgan Stanley Global Healthcare Conference
09/14/18 at 1:00 p.m. ET
AtriCure, Inc. at Morgan Stanley Global Healthcare Conference
Friday, September 14, 2018 1:00 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
11/08/18AtriCure to Present at the Piper Jaffray 30th Annual Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--Nov. 8, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Piper Jaffray 30th Annual Healthcare Conference in New York City on Wednesday, November 28. Management is scheduled to present at 8:00 a.m. Eastern Time. A live audio webcast of the presentation may be acce... 
Printer Friendly Version
11/01/18AtriCure Reports Third Quarter 2018 Financial Results
Worldwide revenue of $49.9 million – an increase of 18.5% year over year U.S. revenue of $39.8 million – an increase of 19.1% year over year International revenue of $10.2 million – an increase of 16.2% year over year MASON, Ohio--(BUSINESS WIRE)--Nov. 1, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage ... 
Printer Friendly Version
10/22/18AtriCure to Participate in Upcoming Investor Conferences
MASON, Ohio--(BUSINESS WIRE)--Oct. 22, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will be participating in upcoming investor conferences. AtriCure is scheduled to present at the Stifel 2018 Healthcare Conference in New York City on Wednesday, November 14, 2018. Management is scheduled to present at... 
Printer Friendly Version
10/11/18AtriCure to Announce Third Quarter 2018 Financial Results
MASON, Ohio--(BUSINESS WIRE)--Oct. 11, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its third quarter 2018 financial results on Thursday, November 1, 2018. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, November 1, 2018 to discuss its third quarter 2018 financial ... 
Printer Friendly Version
10/04/18AtriCure Announces Pricing of Public Offering of Common Stock
MASON, Ohio--(BUSINESS WIRE)--Oct. 4, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced the pricing of its underwritten offering of 2.5 million shares of its common stock at a price to the public of $30.75 per share pursuant to its existing shelf registration statement. Net proceeds to AtriCure from the offering are expected to be approximatel... 
Printer Friendly Version
10/03/18AtriCure Reports Preliminary Financial Results for Third Quarter 2018
MASON, Ohio--(BUSINESS WIRE)--Oct. 3, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced preliminary financial results for the third quarter of 2018. Preliminary and unaudited revenue for the third quarter of 2018 is expected to be approximately $49.9 million, reflecting growth of approximately 18.5% over the third quarter... 
Printer Friendly Version
10/03/18AtriCure Announces Proposed Public Offering of Common Stock
MASON, Ohio--(BUSINESS WIRE)--Oct. 3, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced it has commenced an underwritten public offering of 2.5 million shares of its common stock pursuant to its existing shelf registration statement. In connection with this offering, AtriCure plans to grant the underwriters of the offering a 30-day option to p... 
Printer Friendly Version
08/28/18AtriCure Announces Completion of Patient Enrollment in the CONVERGE IDE Clinical Trial
Landmark study is the first prospective, randomized study comparing the Convergent approach to endocardial catheter ablation in persistent and long-standing persistent atrial fibrillation patients MASON, Ohio--(BUSINESS WIRE)--Aug. 28, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has completed enrollment of the full cohor... 
Printer Friendly Version
08/21/18AtriCure to Present at the Morgan Stanley Global Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--Aug. 21, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Morgan Stanley Global Healthcare Conference at the Grand Hyatt Hotel in New York on Friday, September 14, 2018. Management is scheduled to present at 1:00 p.m. Eastern Time. A live audio webcast of the presentation... 
Printer Friendly Version
08/01/18AtriCure Reports Second Quarter 2018 Financial Results
Updates 2018 Financial Outlook Worldwide revenue of $51.8 million – an increase of 14.5% year over year U.S. revenue of $40.8 million – an increase of 14.9% year over year International revenue of $11.0 million – an increase of 13.1% year over year Positive adjusted EBITDA of $0.8 million MASON, Ohio--(BUSINESS WIRE)--Aug. 1, 2018-- AtriCure, Inc.... 
Printer Friendly Version
07/16/18AtriCure to Present at the Canaccord Genuity 38th Annual Growth Conference
MASON, Ohio--(BUSINESS WIRE)--Jul. 16, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Canaccord Genuity 38th Annual Growth Conference at the Intercontinental Hotel in Boston on Thursday, August 9, 2018. Management is scheduled to present at 12:00 p.m. Eastern Time. A live audio webcast of t... 
Printer Friendly Version
07/11/18AtriCure to Announce Second Quarter 2018 Financial Results
MASON, Ohio--(BUSINESS WIRE)--Jul. 11, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its second quarter 2018 financial results on Wednesday, August 1, 2018. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Wednesday, August 1, 2018 to discuss its second quarter 2018 financial ... 
Printer Friendly Version
06/12/18AtriCure Announces 2018 Analyst and Investor Meeting
MASON, Ohio--(BUSINESS WIRE)--Jun. 12, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, will host an analyst and institutional investor meeting on Tuesday, June 26, 2018, in New York City from 8:30 a.m. to approximately 10:00 a.m. Eastern Time. The meeting will focus on clinician guest speakers to provide expert perspectives on broad trends in ... 
Printer Friendly Version
06/05/18AtriCure and Baheal Group Establish Partnership and China Distribution Agreement
Baheal will serve as the exclusive distribution partner for AtriCure products across China MASON, Ohio--(BUSINESS WIRE)--Jun. 5, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has partnered with Baheal Pharmaceutical Group in China to distribute AtriCure’s surgical ablation devices. This new multi-year agreement establishes... 
Printer Friendly Version
04/26/18AtriCure Reports First Quarter 2018 Financial Results
Worldwide revenue of $47.0 million – an increase of 13.9% year over year U.S. revenue of $38.4 million – an increase of 15.5% year over year International revenue of $8.6 million – an increase of 6.9% year over year MASON, Ohio--(BUSINESS WIRE)--Apr. 26, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (... 
Printer Friendly Version
04/05/18AtriCure to Announce First Quarter 2018 Financial Results
MASON, Ohio--(BUSINESS WIRE)--Apr. 5, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2018 financial results on Thursday, April 26, 2018. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, April 26, 2018 to discuss its first quarter 2018 financial re... 
Printer Friendly Version
03/15/18AtriCure to Present at the Needham & Company’s 17th Annual Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--Mar. 15, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Needham & Company’s 17th Annual Healthcare Conference at the Westin Grand Central in New York on Tuesday, March 27, 2018. Management is scheduled to present at 1:30 p.m. Eastern Time. A live audio webcast ... 
Printer Friendly Version
02/26/18AtriCure Reports Fourth Quarter and Full Year 2017 Financial Results
2017 worldwide revenue of $174.7 million – an increase of 12.6% year over year 2017 U.S. revenue of $138.4 million – an increase of 13.1% year over year 2017 international revenue of $36.3 million – an increase of 11.0% year over year MASON, Ohio--(BUSINESS WIRE)--Feb. 26, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib)... 
Printer Friendly Version
02/22/18AtriCure Launches the AtriClip® FLEX•V™ Device in the United States
New device builds on the “V” clip technology, offering increased flexibility in left atrial appendage management MASON, Ohio--(BUSINESS WIRE)--Feb. 22, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM), today announced that it has launched the AtriClip FLEX•V™ Left Atrial Appendage (LAA) Exclusion System in the United States. The new AtriCli... 
Printer Friendly Version
02/20/18AtriCure Names Scott Drake Board Chairman
Richard Johnston and Elizabeth D. Krell, Ph.D. are Retiring from the Board of Directors in May MASON, Ohio--(BUSINESS WIRE)--Feb. 20, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that Scott Drake has been named Board Chairman, effective at the annual meeting in May of this year. Concurrent with this appointment... 
Printer Friendly Version
02/07/18AtriCure to Announce Fourth Quarter and Full Year 2017 Financial Results
MASON, Ohio--(BUSINESS WIRE)--Feb. 7, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its fourth quarter and full year 2017 financial results on Monday, February 26, 2018. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Monday, February 26, 2018 to discuss its fourth quarter and fu... 
Printer Friendly Version
01/08/18AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2017
MASON, Ohio--(BUSINESS WIRE)--Jan. 8, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced preliminary financial results for the fourth quarter and full year 2017 and provided 2018 financial guidance. Preliminary and unaudited revenue for fourth quarter 2017 is expected to be approximately $46.1 million, reflecting growth of... 
Printer Friendly Version